Pharmacists and GPs are reporting the worst drug shortages on record across the NHS, with structural underfunding, a chronic volume of supply disruptions, and rising global freight costs converging to strain England's medicines supply chain.

The National Pharmacy Association warned on 28 January 2026 that the NHS was underfunding vital medicines by as much as 80% — a gap that leaves dispensing contractors absorbing losses on essential items and, in practice, disincentivises stocking them at adequate volumes. That funding floor sits beneath everything else: even where medicines are physically available, the reimbursement mechanism can make it economically rational for a pharmacy to limit supply.

The upstream picture is no less fraught. Drug manufacturers reported an average of 28 supply issues to the government per week over the five years to October 2025, according to the Pharmaceutical Journal. That figure — roughly four notifications every working day — points to a system operating under near-continuous disruption rather than episodic crisis. It also suggests that the current visible crunch is less an acute shock than the accumulation of unresolved chronic stress.

Global logistics have added a new layer of pressure. Britain has so far avoided direct medicine shortages linked to the war in the Middle East, but soaring freight costs are squeezing generic medicine supplies, Reuters reported on 20 March 2026. Generic medicines — which account for the overwhelming majority of NHS dispensed items by volume — are particularly exposed because their thin margins leave manufacturers and importers little buffer to absorb higher shipping costs before supply decisions are affected.

Institutional Responses and Their Limits

The Royal Pharmaceutical Society's 'Medicines Shortages: One Year On' report, published on 24 March 2026, acknowledged progress but concluded that decisive further steps remain necessary. The RPS, alongside the ABPI, has consistently identified three operational levers: earlier notification of impending shortages, better cross-system communication, and greater delegated authority for frontline pharmacists to substitute or adapt when a product is unavailable. All three have been on the policy agenda for years. The fact that the RPS felt it necessary to restate them a year on indicates the pace of implementation has not matched the pace of deterioration.

NHS England's response at the demand side has been notably softer. On 23 March 2026, NHS England guidance for London urged patients to check what medicines they already had at home before reordering, framing the ask in terms of reducing waste and preventing shortages. Demand-side messaging has a legitimate place in shortage management — over-ordering by patients does create localised stockpiling — but it does not address manufacturer-level supply constraints, reimbursement failures, or freight cost exposure. Leaning on patient behaviour while structural fixes lag is a signal of where the bandwidth is going.

Community Pharmacy England continues to maintain a live shortages resource updated as recently as 11 May 2026, providing dispensers with practical workarounds. That operational layer matters. Pharmacists navigating day-to-day shortages need current, granular information to make safe substitution decisions, and CPE's resource provides exactly that. But it is, by design, a coping mechanism rather than a remedy.

The structural picture that emerges is one of layered vulnerabilities with no single choke point. Reimbursement rates that do not reflect actual acquisition costs, a manufacturer notification system that generates nearly 1,500 alerts a year without triggering proportionate systemic reform, a generics supply chain exposed to global freight volatility, and an institutional reform agenda that is moving — but not quickly enough. The RPS's call for empowering frontline professionals is the most tractable near-term lever: it requires no capital, only regulatory and NHS contractual will. The reimbursement question is harder, sitting at the intersection of Treasury spending constraints and DHSC procurement policy.

Whether the current shortage profile tips from structural stress into a more acute public health event will depend substantially on whether freight costs stabilise and on how quickly the delegated-authority reforms that pharmacists and the RPS are requesting actually reach the dispensing counter.